Psychiatric Medication, Practically

Week Three on Strattera With No Difference: The Non-Stimulant Timeline

Save

No difference at week three of Strattera is usually still within the normal window: atomoxetine typically needs four to eight weeks, sometimes longer, for its full effect. That contrast surprises anyone who has taken a same-day stimulant. Here is the realistic curve, what early response looks like, and when a review helps.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Is week three too early to judge Strattera?

For most people, yes. According to the National Institute of Mental Health, non-stimulant ADHD medications like atomoxetine take longer to begin working than stimulants -- benefits emerge over weeks of consistent daily use rather than on day one 1. Four to eight weeks is the range prescribers commonly describe for a fair trial, and some responses continue strengthening after that. Week three, in other words, is often the trough of the experience: any start-up side effects have made themselves known, while the payoff has not yet arrived. Frustration here is common enough that it is practically part of the timeline. Judging the medication now is like judging a course after the second lecture.

Why does the stimulant comparison mislead?

If you have previously taken Adderall or Ritalin, your calibration for "working" is hours, not weeks -- stimulants produce a felt shift the same day. Atomoxetine operates differently: it gradually changes norepinephrine signaling with steady daily exposure, so there is no arrival moment to notice 1. People switching from a stimulant often interpret that absence as failure by week two or three. The comparison in how the two ADHD stimulants differ shows what fast-acting looks like; atomoxetine simply belongs to a different category, closer in rhythm to how antidepressants build. Resetting the internal clock from "do I feel it today" to "what has changed since last month" is the single most useful adjustment.

What does early response actually look like?

Atomoxetine response tends to announce itself quietly and secondhand. Common first signals: tasks getting finished slightly more often, fewer misplaced items, less mental churn at bedtime, or someone close to you remarking that you seem less scattered -- before you feel subjectively different. Because the change is gradual, contemporaneous notes beat memory: two lines a day on focus, follow-through, and irritability create the record that makes week six evaluable 2. A useful comparison point is how soon results typically show with ADHD medication across drug classes. If week three truly shows nothing, that is data worth keeping, not proof of a verdict already reached.

When is "nothing yet" worth a prescriber review?

Two situations move this from patience to conversation. First, the calendar: if six to eight weeks of consistent daily use pass with no detectable change, prescribers typically reassess -- the trial has been fair and the data is in 1. Second, tolerability: if side effects like nausea, fatigue, or mood changes are costing more than the medication is returning, that conversation should happen sooner; the pattern is described in nauseous and tired on Strattera. Worth asking at any review: whether the current plan reflects your response so far, and what the next option would be if this one stalls. Never wind the medication down yourself to test the question -- what stopping involves is its own topic, covered in what happens if Strattera is stopped.

When a clinician helps

A check-in with your prescriber makes sense at the six-to-eight-week mark regardless of outcome -- to confirm a response, or to plan the next step if there is none. Research on treatment preferences finds that people do best on plans they actually believe in, and prescribers expect this conversation as part of ADHD care rather than treating it as a complaint 2. Bring your notes, name what has and has not changed, and ask directly how much longer a fair trial runs. Free, confidential referral lines such as SAMHSA's National Helpline can also connect you with care if you do not currently have a prescriber managing the question 3.

Common questions

Prescribers generally describe four to eight weeks of consistent daily use as a fair trial, with some responses continuing to build after that. The judgment call at the end of that window belongs in a prescriber conversation.

No. Atomoxetine's benefits typically emerge gradually between weeks four and eight, and early silence is common among eventual responders.

Stimulants do act faster, but speed is only one factor -- prescribers weigh history, side effects, other conditions, and what atomoxetine was chosen to avoid. That trade-off discussion is worth having openly at your next review.

Ending or interrupting atomoxetine is a prescriber decision, not a self-test. An abrupt stop muddies the trial you have already invested weeks in, and your prescriber may see options you cannot.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Watch for these while waiting on the timeline

  • —New or worsening thoughts of self-harm -- atomoxetine carries a monitoring warning for this in young people
  • —Yellowing skin or eyes, dark urine, or unexplained abdominal pain
  • —Fainting, chest pain, or a racing heart
  • —Mood changes that feel severe or unlike you

This article describes typical response timelines for atomoxetine; it is general education, not medical advice about your prescription. Decisions about continuing, changing, or ending a medication belong with your prescriber. If you are in crisis, call or text 988 (Suicide & Crisis Lifeline), free and available 24/7.

References

  1. 1.National Institute of Mental Health (NIMH) (2024). Mental Health Medications. National Institute of Mental Health (NIMH). link ✓ssri-anti-anxiety-medsptsd-medicationdepression-treatmentdrinking-on-antidepressants
  2. 2.McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW (2013). Patient Preference for Psychological vs Pharmacologic Treatment of Psychiatric Disorders: A Meta-Analytic Review. The Journal of Clinical Psychiatry. doi:10.4088/JCP.12r07757 ✓treatment-preferencetherapy-vs-medicationshared-decision-making
  3. 3.Substance Abuse and Mental Health Services Administration (2025). National Helpline for Mental Health, Drug, Alcohol Issues. Substance Abuse and Mental Health Services Administration (SAMHSA). link ✓treatment-accesscrisis-supporthelp-seeking

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library